Karyn A. Goodman, MD, MS
Professor of Radiation Oncology
Grohne Chair of Clinical Oncology
University of Colorado, Aurora, CO
Dr. Goodman is a board-certified radiation oncologist specializing in cancers of the gastrointestinal tract, including malignancies of the esophagus, stomach, pancreas, and liver as well as colorectal and anal cancers. She recently joined the University of Colorado as a Professor in the Department of Radiation Oncology. Dr. Goodman moved to University of Colorado Cancer Center from the Memorial Sloan-Kettering Cancer Center in New York where she had been a faculty member for over eight years. Her initial faculty position was in the Department of Radiation Oncology at Stanford University School of Medicine.
Dr. Goodman obtained her undergraduate and medical degrees from Stanford University and spent a year as a Research Fellow at the Division of Reproductive Health of Centers for Disease Control in Atlanta. She completed her residency training in Radiation Oncology at Memorial Sloan-Kettering Cancer Center where she served as Chief Resident. She earned a Masters in Epidemiology at the Harvard School of Public Health in 2006.
Dr. Goodman’s interests include image-guide radiation therapy, stereotactic body radiotherapy, and intensity modulated radiotherapy treatment planning for gastrointestinal cancers with the intent of reducing toxicity and improving results with radiation therapy. She has also focused her research on quality of life and late effects after radiotherapy. In addition to her interest in technical advances in radiation oncology, she is involved in the development of therapeutic protocols combining radiation, chemotherapy, and targeted agents for gastrointestinal cancers. She has been selected for inclusion in Castle Connolly’s list of America’s Top Doctors for several years.
Dr. Goodman is an internationally recognized expert in Gastrointestinal Cancer and has served in numerous leadership roles on multiple ASTRO, ASCO, and RTOG/NRG committees. She serves as the national Radiation Oncology principal investigator of the RTOG/NRG 0848 study, a phase III trial evaluating the use of post-operative radiotherapy for pancreatic cancer. She is the national Study Chair for the recently completed CALGB/Alliance Cooperative Group phase II trial (CALGB 80803) investigating PET scan-directed therapy for esophageal cancer. She has published over 100 peer-reviewed articles, review articles, and chapters.
In addition to clinical activities in the area of GI cancers, she is assuming the role of Medical Director of the Clinical Trials Office of the University of Colorado Cancer Center and also serves as Associate Medical Director of the UC Health Oncology Services line.